Topical Collection

Autophagy in Cancer and Metastasis

Message from the Collection Editors

Autophagy is a conserved catabolic process necessary for cells to maintain homeostasis and to respond to different environmental stresses through the recycling of their damaged cellular proteins, organelles, and other cellular components. Alteration in autophagy machinery may lead to diverse pathological conditions, including cancer. A close relationship between autophagy, malignant transformation, and cancer progression has been demonstrated in recent decades. Emerging evidence shows a role for autophagy in the modulation of tumor cell motility and invasion, in the promotion and maintenance of the stem-cell phenotype, in drug resistance, in tumor dormancy, and in immune surveillance, all of which are involved in the survival of cancer cells and in the development of metastases. Autophagy has both pro- and anti-tumorigenic roles, depending on the oncogenic context and the stage of tumorigenesis.This Topical Collection provides a general overview of how autophagy affects cancer growth and modulates the development and spread of metastases.

Collection Editors

Dr. Paola Maroni
Prof. Dr. Giovanni Lombardi
Dr. Marta Gomarasca

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/112805

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).